Algernon NeuroScience
  • HOME
  • ABOUT
    • Overview
    • Structure & Valuation
    • Management Team
    • Board of Directors
    • Medical & Scientific Advisors
  • PIPELINE
    • Overview
    • DMT Program For Stroke
    • DMT Program For Traumatic Brain Injury (TBI)
  • INVEST
  • NEWS & MEDIA
    • News Releases
    • Presentations
    • Events
    • Videos & Articles
  • COMPANY
    • Company
    • Our Team
    • Presentations
    • Contacts
    • FAQ
  • CONTACT
Select Page
Mackie Research sets a speculative target of $.80 per share for Algernon Pharmaceuticals

Mackie Research sets a speculative target of $.80 per share for Algernon Pharmaceuticals

Aug 23, 2020

MACKIE RESEARCH REPORT SUMMARY   ALGERNON PHARMACEUTICALS INC. – SPECULATIVE BUY We are initiating coverage of Algernon Pharmaceuticals (AGN-CSE) with a SPECULATIVE BUY recommendation and a target price of $0.80/share. Banking on a Unique Drug Repurposing...

Recent Posts

  • Algernon CEO Discusses Ifenprodil Sale to Seyltx and DMT as a Treatment for Stroke and TBI
  • How Algernon Pharmaceuticals is Unlocking Sub-Psychedelic DMT for Stroke and TBI Treatment
  • The Dales Report – Why Psychedelic Treatments Will Benefit Investors and Healthcare
  • Radius Research Interview – Algernon NeuroScience Initiates TBI Research Program with DMT
  • Proactive Investors CEO Interview – Algernon NeuroScience completes first dosing in Phase 1 clinical study of DMT

Recent Comments

No comments to show.

Subscribe to Algernon NeuroScience

Sign up today and receive company media releases and updates straight to your inbox.

Thank you for your subscription

Subscribe

  • HOME
  • INVEST
  • ABOUT
  • PIPELINE
  • NEWS & MEDIA
  • COMPANY
  • CONTACT
  • Follow
  • Follow
  • Follow

© Algernon NeuroScience – All Rights Reserved 2026      Privacy Policy